This article is a correction to:
Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness, and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer
Sylvanus Kampo1,2,3
Bulbul Ahmmed4Tingting Zhou1,2Lawrence Owusu5
Thomas Winsum Anabah3
Natacha Raissa Doudou6Eugene Dogkotenge Kuugbee7Yong Cui8Zhili Lu9Qiu Yan4Qing-Ping Wen1,2*- 1Department of Anesthesiology, Dalian Medical University, Dalian, China
- 2Department of Anesthesiology, First Affiliated Hospital of Dalian Medical University, Dalian, China
- 3Department of Anesthesia and Intensive Care, School of Medicine and Health Science, University for Development Studies, Tamale, Ghana
- 4Department of Biochemistry and Molecular Biology, Dalian Medical University, Dalian, China
- 5Department of Biotechnology, Dalian Medical University, Dalian, China
- 6Department of Radiology, Dalian Medical University, Dalian, China
- 7Department of Clinical Microbiology, School of Medicine and Health Science, University for Development Studies, Tamale, Ghana
- 8School of Life Science and Bio-pharmaceutics, Shenyang Pharmaceutical University, Shenyang, China
- 9Department of Ophthalmology, First Affiliated Hospital of Dalian Medical University, Dalian, China
A Corrigendum on
Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness, and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer
By Kampo S, Ahmmed B, Zhou T, Owusu L, Anabah TW, Doudou NR., Kuugbee ED, Cui Y, Lu Z, Yan Q, and Wen Q-P. (2019). Front. Oncol. 9:21. doi: 10.3389/fonc.2019.00021
In the original article, there was a mistake in Figure 2 as published. We acknowledge making a mistake with the western blot used for Oct 4 in Figure 2D. The corrected Figure 2 appears below.
FIGURE 2
Figure 2 PTX3 expression in breast cancer cells is associated with stem-like features and epithelial-mesenchymal transition. (A) Tumorsphere formation of MCF-7 and MDA-MB-231 cells. MCF-7 and MDA-MB-231 cells were treated with siPTX3 or rhPTX3 for 14 days, and tumor spheres expansion were analyzed at 40x magnification under a microscope (bar = 50µm; magnification, 400x). (B) PTX3 promotes cell migration and invasion in breast cancer. MCF-7 and MDA-MB-231 cells were treated with either siPTX3 or rhPTX3. The migration and invasion abilities of the cells were examined by migration and invasion assay (Transwell assay). (C, D) Effect of PTX3 on stem-like features and epithelial-mesenchymal transition markers. siPTX3 or rhPTX3-treated MDA-MB-231 and MCF-7 cells were lysed and subjected to 12% SDS-PAGE and analyzed by western blotting with antibodies against PTX3, Oct4, Sox2, E-cadherin, N-cadherin, and Snail. GAPDH was used as an internal control. The data was statistically significant at *P < 0.05 as compared to control. Data are represented as mean ± SEM of three independent experiments.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: scorpion venom analgesic peptide, rBmK AGAP, stemness, epithelial-mesenchymal transition, pentraxin 3, Wnt/β-catenin signaling, transcription factor NF-κB, breast cancer
Citation: Kampo S, Ahmmed B, Zhou T, Owusu L, Anabah TW, Doudou NR, Kuugbee ED, Cui Y, Lu Z, Yan Q and Wen Q-P (2021) Corrigendum: Scorpion Venom Analgesic Peptide, BmK AGAP Inhibits Stemness and Epithelial-Mesenchymal Transition by Down-Regulating PTX3 in Breast Cancer. Front. Oncol. 11:639813. doi: 10.3389/fonc.2021.639813
Received: 09 December 2020; Accepted: 13 May 2021;
Published: 29 June 2021.
Copyright © 2021 Kampo, Ahmmed, Zhou, Owusu, Anabah, Doudou, Kuugbee, Cui, Lu, Yan and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Qing-Ping Wen, wqp.89@163.com